Aminophylline is a drug combination of theophylline and ethylenediamine in a ratio of 2 to 1. It is FDA approved for relieving symptoms of reversible airway obstruction due to asthma or other chronic lung diseases like chronic bronchitis and emphysema. It is also used to prevent apnea in preterm infants.
Non-FDA approved uses include:
Aminophylline's mechanism of action is not entirely understood. Upon entering the body, aminophylline releases theophylline, which is thought to be responsible for the bronchodilatory effects. There are various proposals for the molecular mechanism for theophylline, but not all of them take place at clinically effective concentrations. Theophylline works in three distinct ways as:
Theophylline causes non-selective inhibition of type III and type IV isoenzymes of phosphodiesterase, which leads to increased tissue cyclic adenine monophosphate (cAMP) and cyclic 3′,5′ guanosine monophosphate concentrations, resulting in smooth muscle relaxation in lungs and pulmonary vessels, diuresis, CNS and cardiac stimulation. The bronchodilatory effect is not maximal at therapeutically effective dosages. Inhibition of type IV isoenzyme is responsible for inhibiting the release of mediators from the alveolar macrophages but requires much higher serum concentrations.
Adenosine receptor antagonist
Theophylline antagonizes adenosine receptor A1, A2 strongly, and A3 less potently. It binds to adenosine A2B receptors to prevent bronchoconstriction by inhibiting the release of mediators like histamine and leukotrienes from mast cells. This activity is thought to play an indirect role in the bronchodilation. Theophylline also increases calcium uptake through the adenosine-mediated calcium channels in the diaphragm leading to increased contraction and reversal of diaphragm fatigue. This antagonism of the adenosine receptors, specifically A1 receptors, is responsible for some of the side effects of theophylline like seizures and cardiac arrhythmias.
Histone deacetylase activator
In inflammatory states, the activity of histone deacetylase becomes reduced due to oxidative stress via the activation of phosphoinositide-3-kinase-delta (PI3K-delta). Theophylline increases the activity and recruitment of histone deacetylases to the site of active inflammation at therapeutic concentrations. This action prevents the transcription of inflammatory genes that require acetylation of histones to activate their transcription and also decreases the resistance to steroids of COPD macrophages. This mechanism is distinct from PDE and adenosine receptor inhibition.
A new study indicates that aminophylline plays an essential role in mitochondrial biogenesis in epithelial cells of the lung. Treatment with aminophylline induces the expression of transcriptional coactivator PGC-1α and transcriptional factors NRF1 and TFAM, which requires the activation of the CREB-PGC-1a signaling pathway by aminophylline.
Aminophylline is rapidly and completely absorbed by the body and converted to theophylline, which is up to 40% bound by albumin. The remaining unbound theophylline distributes freely throughout the body except for body fat. The volume of distribution ranges from 0.3 to 0.7 L/kg. It passes across the placenta and is present in breast milk. Theophylline metabolism occurs in the liver via the cytochrome CYP450 system. At lower concentration's it is a substrate of CYP1A2, and at higher concentrations, CYP2E1 may also have involvement. Pharmacokinetics of theophylline are not predictable by sex, age, or other characteristics. Besides, various other factors like certain illnesses, tobacco use, marijuana use, and co-administration of other drugs can significantly alter its clearance. Below is a list of factors affecting the clearance of theophylline.
Factors that increase clearance are:
Factors that decrease clearance are:
Aminophylline comes in the form of an oral solution, oral tablets, and extended-release- tablets. The absorption of the solution and oral tablets give wide fluctuations of serum concentrations and therefore are usually not recommended. The extended-release tablets are absorbed slowly over 12 to 24 hours and provide a steady plasma concentration. The recommended dose ranges from 400 to 600 mg/day.
Intravenous administration of aminophylline occurs via two methods. A loading dose is given to achieve a serum concentration of 10 mcg/ml. Once the serum concentration has reached 10 to 15 mcg/ml, the maintenance constant infusion follows. The dosage given depends on the clearance of theophylline and whether the person has taken theophylline in the last 24 hours. These dosages vary by age, body weight, and the health status of the patient.
The loading dose is 5.7 mg/kg based on the ideal body weight for all age groups.
Loading doses should be administered over 30 minutes at a rate not to exceed 21 mg/hr and should be calculated using ideal body weight. This dose is for patients who have not taken aminophylline in the past 24 hours. The loading dose calculation must use the formula given below for patients who have taken aminophylline in the last 24 hours.
Loading dose = (Desired concentration - measured concentration) (volume of distribution)
Mean volume of distribution: 0.3 to 0.7 ml/kg
Up to 1 mg/kg/hour as a constant infusion can be given depending on the ideal body weight and clearance rates.
IM administration is not recommended due to severe pain at the injection site.
These dosage forms are not widely used due to unreliable absorption and the occurrence of proctitis.
Patients with hepatic dysfunction due to cirrhosis or any other cause require a dose adjustment. The maximum dose for such patients can't exceed 400 mg/day.
There are no dose adjustments needed for renal impairment in adults or children older than 3 months. However, in infants younger than 3 months, a large amount of theophylline is excreted in the urine, and they require a dose adjustment.
Due to varying clearance rates for different concurrent illnesses, a good rule of thumb is that the maximum dose should not exceed 400 mg daily.
Smokers require a higher dose as their clearance rates of theophylline are faster than non-smokers.
Aminophylline has a narrow therapeutic index and is associated with a wide range of adverse effects. The adverse effects depend on the peak serum concentrations of theophylline in the body.
With peak serum concentrations under 20 mcg/ml, the most common adverse effects are similar to the transient effects of caffeine (structurally similar) and include:
Once the serum theophylline exceeds 20 mcg/mL, the chances of adverse events increases and include :
Some of the more serious side effects along with their symptoms from the above mentioned are:
Aminophylline contraindications include patients with hypersensitivity to theophylline, ethylenediamine, or any component of the drug formulation.
Precautions are necessary for patients with concurrent illnesses like:
Aminophylline is a pregnancy category C drug and passes into breast milk and across the placenta. Consistent monitoring and dose adjustment can help prevent adverse effects in this population.
Patients taking aminophylline require monitoring for CNS effects, respiratory rate, arterial blood gasses, and serum theophylline concentrations. Clinicians must measure serum concentrations before initiating a loading dose in a person who has taken theophylline in the last 24 hours. A repeat serum concentration is necessary before starting the maintenance dose, as well.
Theophylline toxicity can present as:
The treatment is mainly supportive and focused on reducing the absorption of aminophylline from the gut. Activated charcoal and sorbitol have shown to slow the absorption from the gastrointestinal system if aminophylline was taken orally. Hemoperfusion and hemodialysis are options as a last resort in patients with severe theophylline toxicity.
Aminophylline is an adjunct to beta2-agonists and corticosteroids in the treatment of reversible bronchoconstriction caused by asthma and chronic lung conditions. The drug demonstrates a narrow therapeutic index, and even with regular monitoring can lead to adverse effects. Healthcare workers, including nurses, pharmacists, and prescribing clinicians, should be aware of the complications of aminophylline toxicity. Without proper management, the morbidity and mortality from aminophylline overdose are high. Patients who receive this agent must be monitored for serum concentrations of the drug to ensure they are within therapeutic serum concentrtions. There is no specific antidote to reverse toxicity, so it is vital to avoid taking high doses without approval from the clinician.
Also, drug interactions and concurrent illnesses require strong consideration before initiating treatment as clearance rates vary widely. The pharmacist should suggest a safer option for the treatment of asthma to clinicians who prescribe this drug and should verify dosing as well as perform thorough medication reconciliation, alerting the team to any issues. Nursing can monitor for adverse events, drug-drug interactions, and treatment effectiveness, also communicating with the healthcare team should they notice anything significant. Only through a collaborative, interprofessional team approach can the morbidity of this medication be lowered while achieving improved outcomes. [Level V]
|||Armanian AM,Badiee Z,Afghari R,Salehimehr N,Hassanzade A,Sheikhzadeh S,Sharif Tehrani M,Rezvan G, Prophylactic aminophylline for prevention of apnea at higher-risk preterm neonates. Iranian Red Crescent medical journal. 2014 Aug; [PubMed PMID: 25389472]|
|||Rabe KF,Magnussen H,Dent G, Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. The European respiratory journal. 1995 Apr; [PubMed PMID: 7664866]|
|||Dent G,Giembycz MA,Rabe KF,Wolf B,Barnes PJ,Magnussen H, Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. American journal of respiratory cell and molecular biology. 1994 May; [PubMed PMID: 8179921]|
|||Polosa R,Blackburn MR, Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease. Trends in pharmacological sciences. 2009 Oct; [PubMed PMID: 19762093]|
|||Mascali JJ,Cvietusa P,Negri J,Borish L, Anti-inflammatory effects of theophylline: modulation of cytokine production. Annals of allergy, asthma [PubMed PMID: 8705632]|
|||Wanke T,Merkle M,Zifko U,Formanek D,Lahrmann H,Grisold W,Zwick H, The effect of aminophylline on the force-length characteristics of the diaphragm. American journal of respiratory and critical care medicine. 1994 Jun; [PubMed PMID: 8004311]|
|||Mattikow MS, Aminophylline improves diaphragmatic contractility. The New England journal of medicine. 1981 Nov 26; [PubMed PMID: 7290162]|
|||To Y,Ito K,Kizawa Y,Failla M,Ito M,Kusama T,Elliott WM,Hogg JC,Adcock IM,Barnes PJ, Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2010 Oct 1; [PubMed PMID: 20224070]|
|||Ranjani R,Vinotha ATS, A prospective randomized controlled study: Theophylline on oxidative stress and steroid sensitivity in chronic obstructive pulmonary disease patients. International journal of pharmaceutical investigation. 2017 Jul-Sep; [PubMed PMID: 29184823]|
|||Cosio BG,Tsaprouni L,Ito K,Jazrawi E,Adcock IM,Barnes PJ, Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. The Journal of experimental medicine. 2004 Sep 6; [PubMed PMID: 15337792]|
|||Wei G,Sun R,Xu T,Kong S,Zhang S, Aminophylline promotes mitochondrial biogenesis in human pulmonary bronchial epithelial cells. Biochemical and biophysical research communications. 2019 Jul 12; [PubMed PMID: 31122698]|
|||Chrystyn H,Mulley BA,Peake MD, Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ (Clinical research ed.). 1988 Dec 10; [PubMed PMID: 3147048]|
|||Teweleit S,Hippius M,Pfeifer R,Hoffmann A, [Rhabdomyolysis as a rare complication of theophylline poisoning]. Medizinische Klinik (Munich, Germany : 1983). 2001 Jan 15; [PubMed PMID: 11210488]|
|||Shannon MW, Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 1997 Jul; [PubMed PMID: 9223689]|